This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Comfrey works primarily through allantoin, a compound that stimulates cell proliferation and accelerates tissue regeneration. Allantoin promotes keratinocyte growth and connective tissue repair, while rosmarinic acid provides anti-inflammatory effects. The mucilage content forms a protective barrier over damaged tissue. This combination makes comfrey effective for wound healing, bone fractures, sprains, and bruises. Evidence level: B, supported by clinical trials and over 2,000 years of traditional use as 'knitbone.'
Is comfrey safe to use during pregnancy?
No, comfrey is unsafe during pregnancy and should be strictly avoided. The pyrrolizidine alkaloids (PAs) in comfrey are hepatotoxic and can cross the placental barrier, potentially causing liver damage to both mother and fetus. These compounds have been linked to veno-occlusive disease and carcinogenic effects. No safe threshold for PA exposure during pregnancy has been established. Breastfeeding women should also avoid comfrey in all forms. Evidence level: B for hepatotoxicity concerns.
Does comfrey interact with any medications?
Topical comfrey has minimal documented drug interactions, but caution is warranted with hepatotoxic medications. Because pyrrolizidine alkaloids can be absorbed through skin and cause liver stress, avoid combining comfrey with drugs like acetaminophen, isoniazid, methotrexate, or other liver-metabolized medications. Internal use is absolutely contraindicated with any medication due to cumulative hepatotoxicity risk. Patients with liver disease should avoid comfrey entirely. Always consult a healthcare provider before combining herbal treatments with prescription drugs.
How often should I apply comfrey cream?
Apply comfrey cream or ointment 2-3 times daily to intact, unbroken skin over the affected area. Treatment should not exceed 6 weeks of continuous use to minimize systemic absorption of pyrrolizidine alkaloids. Use only on closed injuries like sprains, bruises, or unbroken skin over fractures—never on open wounds. A thin layer is sufficient. Discontinue if no improvement occurs after 2 weeks. Evidence level: B for topical use in musculoskeletal injuries.
Why can't comfrey be taken internally?
Comfrey contains pyrrolizidine alkaloids (PAs), which are hepatotoxic and potentially carcinogenic. Internal ingestion can cause hepatic veno-occlusive disease, where liver veins become blocked, potentially leading to liver failure. PAs are not destroyed by cooking or drying. Regulatory agencies including the FDA and EFSA have banned internal use of comfrey products. Topical application on intact skin is considered safer due to minimal systemic absorption, though prolonged use should still be avoided.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Comfrey (Symphytum officinale) is a traditional medicinal plant used topically for inflammation and pain, though its internal use is restricted due to severe hepatotoxicity [PMID:30000832, PMID:41993578].
Background
Symphytum officinale, commonly known as comfrey, is a perennial plant that has been used in traditional medicine for over 2,000 years [PMID:41993578, PMID:21170807].
Traditional uses
In folk medicine, comfrey root has been used to treat swellings, phlebitis, contusions, gastro-duodenal ulcers, respiratory diseases, metrorrhagia, wounds, fractures, and inflammatory conditions [PMID:37506778, PMID:41993578].
Active compounds
Key bioactive constituents include allantoin, rosmarinic acid, pyrrolizidine alkaloids (PAs) such as lycopsamine and intermedine, polysaccharides, lignans, and various phenolic acids and flavonoids [PMID:30000832, PMID:41993578, PMID:21170807, PMID:38252561].
Mechanism of action
Comfrey exerts anti-inflammatory and tissue-regenerative effects primarily by inhibiting NF-κB and MAPK pathways and suppressing pro-inflammatory markers including E-selectin, VCAM1, ICAM1, and COX-2 [PMID:41993578, PMID:31105555].
Clinical evidence
Evidence BPain, inflammation, and swelling of muscles and joints (degenerative arthritis, acute back myalgia, sprains, contusions, strains)
Multiple randomized controlled trials have demonstrated the efficacy and safety of topical comfrey preparations for these conditions, including in children aged 3 or 4 and over [PMID:22359388, PMID:23224633]
Evidence CPost-episiotomy pain and cracked nipples
Scientific evidence of effectiveness for these indications is minimal [PMID:30000832]
Safety & adverse effects
Pyrrolizidine alkaloids in comfrey can cause severe liver damage, liver cancer, mutagenicity, and death [PMID:30000832]. These alkaloids are potentially hepatotoxic, pneumotoxic, genotoxic, and carcinogenic, interacting with DNA in liver endothelial cells and hepatocytes [PMID:26177929, PMID:21170807]. Due to these risks, the U.S. FDA has banned the sale of oral comfrey products [PMID:30000832].
Pregnancy & lactation
Topical use of comfrey during breastfeeding is considered contraindicated by most sources; if used, it should be applied to intact skin away from the breast for a limited duration to ensure the infant does not come into direct contact with the area [PMID:30000832].
Evidence summary
Strong clinical evidence (RCTs) supports the topical use of comfrey for musculoskeletal pain and inflammation, while strong toxicological evidence supports the prohibition of internal use due to hepatotoxicity.
PubMed sources
1.PMID: 30000832 (2006) — The efficacy and safety of comfrey. · Public health nutrition
2.PMID: 22359388 (2012) — Comfrey: a clinical overview. · Phytotherapy research : PTR
3.PMID: 37506778 (2024) — Skin microbiota metabolism of natural products from comfrey root (Symphytum officinale L.). · Journal of ethnopharmacology
4.PMID: 38252561 (2024) — Phytochemical profiling and bioactivity assessment of underutilized Symphytum species in comparison with Symphytum officinale. · Journal of the science of food and agriculture
5.PMID: 41993578 (2026) — Ethnopharmacological insights into Symphytum officinale L.: traditional uses, phytochemical composition, therapeutic potential, and clinical-toxicological implications. · Frontiers in pharmacology
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 26177929 (2016) — The comparative toxicity of a reduced, crude comfrey (Symphytum officinale) alkaloid extract and the pure, comfrey-derived pyrrolizidine alkaloids, lycopsamine and intermedine in chicks (Gallus gallus domesticus). · Journal of applied toxicology : JAT
7.PMID: 23224633 (2013) — Comfrey root: from tradition to modern clinical trials. · Wiener medizinische Wochenschrift (1946)
8.PMID: 31105555 (2019) — A Symphytum officinale Root Extract Exerts Anti-inflammatory Properties by Affecting Two Distinct Steps of NF-κB Signaling. · Frontiers in pharmacology
9.PMID: 21170807 (2010) — Metabolism, genotoxicity, and carcinogenicity of comfrey. · Journal of toxicology and environmental health. Part B, Critical reviews